Incyte: Biotech Company Builds Blockbuster Pipeline Beyond Jakafi – P/E Ratio Below 14!
Reading Time: 3 minutes
Incyte is transforming into a diversified provider in the fields of hematology, oncology, and immunology, in light of the impending patent expiration of Jakafi. With the acquisition of Vega Therapeutics, VGA039 is secured as a therapy for bleeding disorders with blockbuster potential. Opzelura is the largest growth driver outside of Jakafi, with a growth rate of 20%. Povorcitinib is considered the biggest pipeline opportunity as an oral JAK1 inhibitor. Incyte Corporation (INCY) has so far been heavily dependent on its core product...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
